NEW YORK (October 7, 2026) —Mount Sinai Health System has appointed Livia Agnes Veress, MD, as Vice Chair for Research in the Department of Pediatrics and System Chief of Pediatric Pulmonology, effective Tuesday, September 1. She will also serve as a Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and an attending physician at Mount Sinai Kravis Children’s Hospital.
Dr. Veress is an internationally recognized physician-scientist with board certifications in pediatric pulmonology and additional training in pediatric critical care medicine. Her clinical expertise includes complex pediatric airway and lung diseases, including acute respiratory distress syndrome (ARDS), plastic bronchitis, bronchopulmonary dysplasia, bronchiolitis obliterans, chemical inhalation injuries, and interstitial lung disease.
As Vice Chair for Research, Dr. Veress will lead the Jack and Lucy Clark Department of Pediatrics’ research strategy and infrastructure, working closely with the department chair, Grants Administration Office, Pediatric Clinical Trials Office, and research-focused institutes across Mount Sinai, including The Mindich Child Health and Development Institute.
“Mount Sinai has an extraordinary depth of expertise and infrastructure in child health research, and I am excited to help bring those strengths together in new ways,” said Dr. Veress. “My goal is to create an environment where innovative ideas can move from the laboratory and clinical setting toward treatments that make a meaningful difference for children and their families. I am particularly excited to support the next generation of physician-scientists and build collaborations across disciplines.”
As System Chief of Pediatric Pulmonology, Dr. Veress will oversee the division’s clinical, research, and academic strategy across the Mount Sinai Health System. She will also maintain an active clinical practice at Mount Sinai Kravis Children’s Hospital, caring for children with complex respiratory conditions and bringing specialized expertise in pediatric airway and lung disease, acute respiratory distress syndrome, plastic bronchitis, and toxic inhalation injuries.
“Dr. Veress brings together exactly the combination of clinical expertise, scientific leadership, and vision that we need to advance the Department of Pediatrics,” said Lisa M. Satlin, MD, Herbert H. Lehman Professor and Chair, Jack and Lucy Clark Department of Pediatrics, Icahn School of Medicine at Mount Sinai. “Her leadership will strengthen our research enterprise while helping us expand and enhance the care we provide to children with complex pulmonary conditions. We are thrilled to welcome her to Mount Sinai and look forward to the discoveries and opportunities her leadership will bring to our faculty, trainees, patients, and families.” Dr. Satlin is also Pediatrician-in-Chief of Mount Sinai Kravis Children’s Hospital.
Before joining Mount Sinai, Dr. Veress was a Tenured Professor of Pediatrics and Director of the Center for Advanced Drug Development at the University of Colorado Anschutz Medical Campus and Children's Hospital of Colorado. She earned her medical degree from LSU Health New Orleans School of Medicine and completed her pediatric residency at LSU, followed by fellowship training in pediatric critical care medicine and pediatric pulmonology at the University of Colorado Anschutz Medical Campus.
Her research program focuses on bronchopulmonary dysplasia prevention and physiology-based treatment modalities, mechanical ventilation, ventilator-induced lung injury, acute lung injury/ARDS, lung ultrasound development, lung development disorders due to in utero drug and chemical exposures, pulmonary drug toxicities, coagulation abnormalities, endothelial injuries and pulmonary hypertension, opioid overdose-associated lung injury, inhalation injuries, plastic bronchitis, and lung fibrotic disorders. She studies novel fibrinolytic and antifibrotic drug therapies for conditions including plastic bronchitis and chemical inhalation toxicities, with research spanning translational studies to help bring novel drugs from bench to the bedside.
Her work has been supported by multiple National Institutes of Health grants, including R01 and CounterACT U-series awards, and Biomedical Advanced Research and Development Authority contracts from the U.S. Department of Health and Human Services, to strategically support U.S. Food and Drug Administration drug development programs and help improve U.S. civilian rescue operations and disaster response after chemical inhalation events.
###
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.